"Britain's biotech sector is going through unprecedented growth, with substantial investment supporting a myriad of start-ups tackling some of the world's most pressing healthcare challenges. For investors, the sector presents the dual benefits of attractive potential returns alongside achieving a social purpose."
Will Brooks, Investment Director, Downing LLP

"Over the last few years, Pfizer has taken important steps to become an industry leader in gene therapy. Pfizer is currently focused on rare, monogenic diseases, meaning those diseases that are caused by a single faulty gene. We have been following a 'build, partner and buy' strategy for making investments in gene therapy for the past several years. We are focused on leading in this technology by bringing together the foremost expertise in AAV vector design and development with partnerships, in-house knowledge of disease biology and manufacturing capabilities. We currently have three gene therapy programs in the clinic and six preclinical."
Pfizer Inc. spokeswoman Patricia Kelly on Pfizer Inc., which has acquired a 15 percent equity interest in privately held Vivet Therapeutics SAS

"Many neurological disorders are a result of a local dysfunction of a neural circuit. It's either over-firing or under-firing. We want to modulate those that are firing incorrectly."
Elma Hawkins, president and CEO, Redpin Therapeutics Inc., a preclinical gene therapy startup leveraging a chemogenetics approach to hard-to-treat CNS diseases